# Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

> **NCT03078075** · PHASE3 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 403 (actual)

## Conditions studied

- Methamphetamine Use Disorder

## Interventions

- **DRUG:** Naltrexone: Vivitrol®
- **DRUG:** Placebo (PLB) Injectable
- **DRUG:** Bupropion: Wellbutrin XL®
- **DRUG:** Placebo (PLB) Oral

## Key facts

- **NCT ID:** NCT03078075
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-05
- **Primary completion:** 2019-07-03
- **Final completion:** 2019-07-25
- **Target enrollment:** 403 (ACTUAL)
- **Last updated:** 2021-05-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03078075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03078075, "Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03078075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*